首页> 外文期刊>Chemotherapy: International Journal of Experimental and Clinical Chemotherapy >Increased gamma-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin
【24h】

Increased gamma-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin

机译:增加的γ-H2AX和Rad51 DNA修复在人类细胞株中对化学治疗剂氮芥子和顺铂耐药的生物标志物的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Chemotherapeutic anticancer drugs mediate cytotoxicity by a number of mechanisms. However, alkylating agents which induce DNA interstrand crosslinks (ICL) are amongst the most effective anticancer agents and often form the mainstay of many anticancer therapies. The effectiveness of these drugs can be limited by the development of drug resistance in cancer cells and many studies have demonstrated that alterations in DNA repair kinetics are responsible for drug resistance. In this study we developed two cell lines resistant to the alkylating agents nitrogen mustard (HN2) and cisplatin (Pt). To determine if drug resistance was associated with enhanced ICL DNA repair we used immunocytochemistry and imaging flow cytometry to quantitate the number of gamma-H2AX and Rad51 foci in the nuclei of cells after drug exposure. gamma-H2AX was used to evaluate DNA strand breaks caused by repair incision nucleases and Rad51 was used to measure the activity of homologous recombination in the repair of ICL. In the drug-resistant derivative cell lines there was overall a significant increase in the number and persistence of both gamma-H2AX and Rad51 foci in the nuclei of cells over a 72-hour period, when compared to the non-resistant parental cell lines (ANOVA p < 0.0001). In a Pt-resistant ovarian cancer cell line (A2780cis(R)) a similar enhancement of DNA repair was observed when compared to the non-drug-resistant wild-type ovarian cancer cells (A2780) following exposure to HN2. Our data suggest that using DNA repair biomarkers to evaluate mechanisms of resistance in cancer cell lines and human tumours may be of experimental and clinical benefit. We concede, however, that examination of a larger population of cell lines and tumours is required to fully evaluate the validity of this approach. (C) 2015 S. Karger AG, Basel
机译:化学治疗抗癌药物通过多种机制介导细胞毒性。然而,诱导DNA链间交联(ICL)的烷基化剂是最有效的抗癌剂之一,并且经常形成许多抗癌疗法的主体。这些药物的有效性可能受到癌细胞中耐药性发展的限制,许多研究表明,DNA修复动力学的改变是耐药性的原因。在这项研究中,我们开发了两种抗烷化剂氮芥子气(HN2)和顺铂(Pt)的细胞系。为了确定耐药性是否与增强的ICL DNA修复有关,我们使用了免疫细胞化学和成像流式细胞术来量化药物暴露后细胞核中的γ-H2AX和Rad51灶的数量。 γ-H2AX用于评估修复切口核酸酶引起的DNA链断裂,Rad51用于评估ICL修复过程中同源重组的活性。与非耐药亲本细胞系相比,在耐药性衍生细胞系中,在72小时内,γ-H2AX和Rad51病灶在细胞核中的数量和持久性总体上显着增加(方差分析p <0.0001)。与暴露于HN2后的非耐药野生型卵巢癌细胞(A2780)相比,在具有Pt耐药性的卵巢癌细胞系(A2780cis(R))中观察到了类似的DNA修复增强作用。我们的数据表明,使用DNA修复生物标记物评估癌细胞系和人类肿瘤中的耐药机制可能具有实验和临床意义。但是,我们承认,需要检查大量细胞系和肿瘤才能充分评估这种方法的有效性。 (C)2015 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号